PDCD1 and non-small cell lung carcinoma: In addition to CD8+PD-1+ TCI predicting ICB responsiveness, studies in anti-PD-1-treated non-small cell lung cancer (NSCLC) patients found a strong correlation between high CD8+PD-1+ TCI and durable treatment response as well as OS33,34.